Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
EDIT 
Editas Medicine Inc (EDIT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: EDIT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -60.71% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 103.72M USD | Price to earnings Ratio - | 1Y Target Price 3.75 |
Price to earnings Ratio - | 1Y Target Price 3.75 | ||
Volume (30-day avg) 5601015 | Beta 1.87 | 52 Weeks Range 1.12 - 7.41 | Updated Date 03/30/2025 |
52 Weeks Range 1.12 - 7.41 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.88 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -112.28% |
Management Effectiveness
Return on Assets (TTM) -35.52% | Return on Equity (TTM) -98.1% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -131160645 | Price to Sales(TTM) 3.21 |
Enterprise Value -131160645 | Price to Sales(TTM) 3.21 | ||
Enterprise Value to Revenue 1.25 | Enterprise Value to EBITDA -1.36 | Shares Outstanding 82976304 | Shares Floating 82622805 |
Shares Outstanding 82976304 | Shares Floating 82622805 | ||
Percent Insiders 0.32 | Percent Institutions 66.17 |
Analyst Ratings
Rating 3.38 | Target Price 3.75 | Buy - | Strong Buy 4 |
Buy - | Strong Buy 4 | ||
Hold 10 | Sell 2 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Editas Medicine Inc
Company Overview
History and Background
Editas Medicine Inc. was founded in 2013 and is a clinical-stage genome editing company. It is focused on developing therapies based on CRISPR technology. Significant milestones include preclinical validation of their technology, clinical trial initiations, and partnerships with pharmaceutical companies. It evolved from a research-focused entity to a company with clinical-stage assets.
Core Business Areas
- Genome Editing Therapeutics: Develops CRISPR-based therapies for genetic diseases, focusing on in vivo and ex vivo approaches.
Leadership and Structure
The leadership team consists of the CEO, CFO, CSO, and other key executives. The organizational structure comprises research and development, clinical operations, regulatory affairs, and commercial functions.
Top Products and Market Share
Key Offerings
- EDIT-101: An investigational gene editing medicine under development for the treatment of Leber Congenital Amaurosis 10 (LCA10), an inherited form of blindness. There is no available market share data, as this is still in clinical trials. Competitors include other companies developing gene therapies for inherited retinal diseases.
- EDIT-301: An investigational gene editing medicine under development for the treatment of sickle cell disease (SCD). There is no available market share data, as this is still in clinical trials. Competitors include CRISPR Therapeutics and Vertex Pharmaceuticals (CRSP), and bluebird bio (BLUE).
Market Dynamics
Industry Overview
The gene editing industry is rapidly growing, driven by advancements in CRISPR technology and increasing investment in genetic therapies. The market is competitive, with numerous companies pursuing different applications of gene editing.
Positioning
Editas Medicine is positioned as a leader in CRISPR-based gene editing, with a focus on developing treatments for inherited diseases. Their competitive advantage lies in their intellectual property, scientific expertise, and clinical programs.
Total Addressable Market (TAM)
The total addressable market for gene editing therapies is estimated to be in the billions of dollars, with potential applications across a wide range of diseases. Editas is targeting specific genetic diseases within this large market.
Upturn SWOT Analysis
Strengths
- Strong intellectual property portfolio
- Experienced leadership team
- Advanced CRISPR platform
- Clinical-stage assets
Weaknesses
- High cash burn rate
- Clinical trial risks
- Regulatory uncertainty
- Dependence on CRISPR technology
Opportunities
- Expanding pipeline of gene editing therapies
- Partnerships with pharmaceutical companies
- Advancements in gene editing technology
- Increasing market demand for genetic therapies
Threats
- Competition from other gene editing companies
- Adverse clinical trial results
- Regulatory hurdles
- Ethical concerns regarding gene editing
Competitors and Market Share
Key Competitors
- CRSP
- BEAM
- NTLA
Competitive Landscape
Editas faces competition from companies with established CRISPR platforms, strong research capabilities, and advanced clinical programs. Editas' advantages include their scientific expertise and clinical development focus. Their disadvantages include being further behind in a few areas in terms of clinical readiness compared to leaders.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by expansion of R&D activities and progress in clinical trials.
Future Projections: Future growth is dependent on clinical trial successes and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing clinical trials for EDIT-101 and EDIT-301, and expanding the research pipeline.
Summary
Editas Medicine is a clinical-stage company focused on CRISPR-based gene editing. It holds a promising technology, but it is not yet in a position to earn revenue. Successful clinical trials would be critical for revenue generation and market recognition. The company faces stiff competition, and careful monitoring of its cash burn rate will be crucial.
Similar Companies
- CRSP
- BEAM
- NTLA
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Company Website
- Analyst Reports
- Industry News
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual risk tolerance and financial situation.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Editas Medicine Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2016-02-03 | President, CEO & Director Dr. Gilmore O'Neill M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 246 | Website https://www.editasmedicine.com |
Full time employees 246 | Website https://www.editasmedicine.com | ||
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors in collaboration with Bristol Myers Squibb Company ("BMS") through its wholly owned subsidiary, Juno Therapeutics, Inc. It also collaboration and licensing agreement with Immatics to combine gamma-delta T cell adoptive cell therapies and gene editing for the treatment of cancer. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.